Journal
JOURNAL OF CONTROLLED RELEASE
Volume 272, Issue -, Pages 9-16Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2017.12.032
Keywords
Gold nanoparticles; Tumor penetration; Junction opening; Image analysis
Funding
- NIH [1R01CA177272]
- NSF [DMR 1206426]
- solid tumor translational research grant from the Fred Hutchinson Cancer Research Center
- National Science Foundation Graduate Research Fellowship
- NATIONAL CANCER INSTITUTE [R01CA177272] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Carcinomas contain tight junctions that can limit the penetration and therefore therapeutic efficacy of anticancer agents, especially those delivered by nano-carrier systems. The junction opener (JO) protein is a virus-derived protein that can transiently open intercellular junctions in epithelial tumors by cleaving the junction protein desmoglein-2 (DSG2). Co-administration of JO was previously shown to significantly increase the efficacy of various monoclonal antibodies and chemotherapy drugs in murine tumor models by allowing for increased intratumoral penetration of the drugs. To investigate the size-dependent effect of JO on nanocarriers, we used PEGylated gold nanoparticles (AuNPs) of two different sizes as model drugs and investigated their biodistribution following JO protein treatment. By inductively coupled plasma mass spectrometry (ICP-MS), JO was found to significantly increase bulk tumor accumulation of AuNPs of 35 nm but not 120 nm particles in both medium (200-300 mm(3)) and large (500-600 mm(3)) tumors. Image analysis of tumor sections corroborates this JO-mediated increase in tumor accumulation of AuNPs. Quantitative intratumoral distribution analyses show that most nanoparticles were found within 100 mu m of the vasculature, and that the penetration profiles of AuNPs are not significantly affected by JO treatment at the 6 h timepoint.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available